The perindopril/amlodipine/atorvastatin polypill significantly increased high treatment adherence compared to separate pills (60% vs 18%; RR 3.29, 95% CI 2.88-3.75) and reduced healthcare costs.
Cohort (n=2,220)
Does perindopril/amlodipine/atorvastatin administrated as a polypill improve treatment adherence compared to separate pills?
Administration of perindopril/amlodipine/atorvastatin as a single polypill significantly improves treatment adherence and reduces healthcare costs compared to separate pills in a real-world setting.
Effect estimate: RR 3.29 (95% CI 2.88-3.75)
Absolute Event Rate: 60% vs 18%
AIMS: To compare adherence to perindopril/amlodipine/atorvastatin combination administrated as a polypill (one pill) vs. separate tablets. METHODS AND RESULTS: Using the healthcare utilization database of Lombardy (Italy), 1110 patients who received the perindopril/amlodipine/atorvastatin polypill during 2019-2021 were matched with 1110 patients prescribed the same combination in separate tablets or as two antihypertensive drugs in a single tablet and the lipid-lowering drug tablet separately. Adherence to treatment was assessed over the year after the first perindopril/amlodipine/atorvastatin dispensation as the proportion of the follow-up days covered by prescription (PDC). Patients with a PDC >75% and <25% were defined as highly and poorly adherent, respectively. Adherence dynamics over time were evaluated through group-based trajectory modelling. Cardiovascular-related healthcare costs were also assessed. Log-binomial regression models were fitted to estimate the risk ratio (RR) of treatment adherence associated with the administration strategy. Among the polypill and the separate-pill combination users, 60% and 18% of patients showed high adherence, respectively; the corresponding figures for the low adherence were 5% and 37%. Compared with the separate-pill combination, the polypill increased the propensity to be highly adherent to treatment by 3.29 times (95% confidence interval: 2.88-3.75) and reduced the low adherence risk (RR = 0.13, 0.10-0.18), irrespective of sex, age, comorbidities, and co-treatment burden also throughout the entire follow-up. The polypill was also associated with lower costs (€676 vs. €1068, P = 0.003). CONCLUSION: In a real-life setting, the polypill improved treatment adherence and reduced healthcare costs compared to the corresponding separate-pill combination. These findings support current guidelines in favour of the polypill.
Morabito et al. (2025) conducted a cohort in Patients requiring perindopril/amlodipine/atorvastatin combination therapy (n=2,220). Perindopril/amlodipine/atorvastatin polypill vs. Same combination in separate tablets was evaluated on High adherence (proportion of follow-up days covered by prescription >75%) (RR 3.29, 95% CI 2.88-3.75). The perindopril/amlodipine/atorvastatin polypill significantly increased high treatment adherence compared to separate pills (60% vs 18%; RR 3.29, 95% CI 2.88-3.75) and reduced healthcare costs.